Ranbaxy’s arm launches authorized generic version of Caduet in US

07 Dec 2011 Evaluate

Ranbaxy Laboratories’ wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc. has launched an authorized generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.

Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate, presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin. Caduet generated total annual sales of $339 million in the US, as per IMS - MAT September 2011. The company is making available the full range of the generic version of Caduet.

Recently, Ranbaxy Laboratories had received US health regulator’s approval to produce generic version of cholesterol lowering drug Lipitor, a move that will help the India-based firm to launch the drug in the American market.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×